Abaxis Inc Stock Upgraded (ABAX)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- Abaxis (Nasdaq: ABAX) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • ABAX's debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 7.80, which clearly demonstrates the ability to cover short-term cash needs.
  • 49.98% is the gross profit margin for ABAXIS INC which we consider to be strong. Regardless of ABAX's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 8.89% trails the industry average.
  • ABAXIS INC's earnings per share declined by 43.3% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past year. However, we anticipate this trend reversing over the coming year. During the past fiscal year, ABAXIS INC reported lower earnings of $0.63 versus $1.23 in the prior year. This year, the market expects an improvement in earnings ($0.90 versus $0.63).
  • ABAX, with its decline in revenue, underperformed when compared the industry average of 2.9%. Since the same quarter one year prior, revenues fell by 15.8%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
  • The share price of ABAXIS INC has not done very well: it is down 7.19% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. Despite the decline in its share price over the last year, this stock is still more expensive (when compared to its current earnings) than most other companies in its industry. We feel, however, that other strengths this company displays compensate for this.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient-care setting to provide blood constituent measurements for clinicians worldwide. Abaxis has a market cap of $971.5 million and is part of the health care sector and drugs industry. Shares are up 8.5% year to date as of the close of trading on Friday.

You can view the full Abaxis Ratings Report or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say

3 Stocks Dragging In The Drugs Industry

Dividend Watch: 3 Stocks Going Ex-Dividend Tomorrow: FCT, ABAX, CBOE

Abaxis (ABAX) Is Today's Strong On High Volume Stock

Credit Suisse's 12 Contrarian Stock Ideas to Sell Now